Canadian application, no grantCanada
Novel bisamidate phosphonate prodrugs
CA 2396713 A1 · Owner: Metabasis Therapeutics, Inc. · Inventors: Kasibhatla, Srinivas Rao; Jiang, Tao; Reddy, K. Raja
Overview
Drawings and full text
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
Novel bisamidate phosphonate prodrugs of FBPase inhibitors of the Formula (IA) and their use in the treatment of diabetes and other conditions associated with elevated blood glucose.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed December 22, 2000. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended December 22, 2020.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by December 22, 2022.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
FiledDecember 22, 2000
GrantedNo grant recorded
Term endedDecember 22, 2020
Patent numberCA 2396713 A1
Classification (IPC)C07F9/65 +2 more
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.